How are hyponatremia, hypernatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypomagnesemia, and hypermagnesemia treated?

Treatment of Electrolyte Imbalances

Hypokalemia Management

For hypokalemia, oral potassium chloride supplementation is the preferred route for most patients, with typical dosing of 20-60 mEq/day divided into 2-3 doses, while intravenous replacement is reserved for severe cases (K+ ≤2.5 mEq/L), ECG abnormalities, or active cardiac arrhythmias. 1

Severity Classification and Initial Assessment

• Mild hypokalemia (3.0-3.5 mEq/L) can often be managed with dietary modification and oral supplementation, targeting a serum potassium of 4.0-5.0 mEq/L 1
• Moderate hypokalemia (2.5-2.9 mEq/L) requires prompt correction due to increased cardiac arrhythmia risk, especially in patients with heart disease or on digitalis 1
• Severe hypokalemia (K+ ≤2.5 mEq/L) demands immediate IV replacement with continuous cardiac monitoring due to extreme risk of ventricular arrhythmias, ventricular fibrillation, and cardiac arrest 1

Critical Pre-Treatment Assessment

Check and correct magnesium levels first—hypomagnesemia is the most common reason for refractory hypokalemia and must be corrected (target >0.6 mmol/L or >1.5 mg/dL) before potassium levels will normalize. 1 Approximately 40% of hypokalemic patients have concurrent hypomagnesemia 1

• Use organic magnesium salts (aspartate, citrate, lactate) rather than oxide or hydroxide due to superior bioavailability 1
• For severe symptomatic hypomagnesemia with cardiac manifestations, administer IV magnesium sulfate per standard protocols 1

Oral Potassium Replacement Protocol

For patients with functional GI tract and K+ >2.5 mEq/L:

• Start with potassium chloride 20-40 mEq daily, divided into 2-3 separate doses 1
• Maximum daily dose should not exceed 60 mEq without specialist consultation 1
• Dividing doses throughout the day prevents rapid fluctuations in blood levels and improves gastrointestinal tolerance 1
• Recheck potassium and renal function within 3-7 days after starting supplementation, then every 1-2 weeks until values stabilize, at 3 months, and subsequently at 6-month intervals 1

Intravenous Potassium Replacement

Indications for IV replacement:

• Severe hypokalemia (K+ ≤2.5 mEq/L) 1
• ECG abnormalities (ST depression, T wave flattening, prominent U waves) 1
• Active cardiac arrhythmias (torsades de pointes, ventricular tachycardia, ventricular fibrillation) 1
• Severe neuromuscular symptoms 1
• Non-functioning gastrointestinal tract 1

IV administration guidelines:

• Standard concentration: ≤40 mEq/L via peripheral line 1
• Maximum rate: 10 mEq/hour via peripheral line 1
• Preferred formulation: 2/3 potassium chloride (KCl) + 1/3 potassium phosphate (KPO4) to address concurrent phosphate depletion 1
• For severe hypokalemia requiring IV replacement, add 20-30 mEq potassium per liter of IV fluid using the 2/3 KCl + 1/3 KPO4 formulation 1
• Recheck serum potassium within 1-2 hours after IV potassium correction to ensure adequate response and avoid overcorrection 1

Special Clinical Scenarios

Diabetic Ketoacidosis (DKA):

• Add 20-30 mEq potassium (2/3 KCl and 1/3 KPO4) to each liter of IV fluid once K+ falls below 5.5 mEq/L and adequate urine output is established 1
• If K+ <3.3 mEq/L, delay insulin therapy until potassium is restored to prevent life-threatening arrhythmias 1

Diuretic-Induced Hypokalemia:

• For persistent hypokalemia despite oral supplementation, adding potassium-sparing diuretics (spironolactone 25-100 mg daily, amiloride 5-10 mg daily, or triamterene 50-100 mg daily) is more effective than chronic oral supplements 1
• Check serum potassium and creatinine within 5-7 days after initiating potassium-sparing diuretic, continuing monitoring every 5-7 days until values stabilize 1
• Avoid potassium-sparing diuretics in patients with significant chronic kidney disease (GFR <45 mL/min) 1

Cardiac Disease Patients:

• Maintain potassium strictly between 4.0-5.0 mEq/L, as both hypokalemia and hyperkalemia increase mortality risk 1
• Even modest decreases in serum potassium increase the risks of using digitalis 1
• Correct hypokalemia before administering digoxin, as hypokalemia increases digoxin toxicity risk 1

Medication Considerations

Avoid or use with extreme caution:

• Most antiarrhythmic agents should be avoided as they can exert important cardiodepressant and proarrhythmic effects in hypokalemia; only amiodarone and dofetilide have been shown not to adversely affect survival 1
• NSAIDs should be avoided entirely as they cause sodium retention, peripheral vasoconstriction, and attenuate treatment efficacy 1

Adjust or temporarily hold:

• In patients taking ACE inhibitors or ARBs alone or with aldosterone antagonists, routine potassium supplementation may be unnecessary and potentially deleterious 1
• When adding aldosterone antagonists, discontinue or significantly reduce potassium supplementation to avoid severe hyperkalemia 1

Common Pitfalls to Avoid

• Never supplement potassium without checking and correcting magnesium first—this is the single most common reason for treatment failure 1
• Failing to monitor potassium levels regularly after initiating therapy can lead to serious complications 1
• Combining potassium-sparing diuretics with ACE inhibitors or ARBs without close monitoring dramatically increases hyperkalemia risk 1
• Not discontinuing potassium supplements when initiating aldosterone receptor antagonists can lead to hyperkalemia 1

---

Hyperkalemia Management

For acute hyperkalemia with ECG changes, immediately administer IV calcium gluconate (10%: 15-30 mL over 2-5 minutes) to stabilize cardiac membranes, followed by insulin 10 units IV with 25 grams dextrose to shift potassium intracellularly. 1

Immediate Interventions for Severe Hyperkalemia (K+ >6.5 mEq/L or ECG Changes)

Cardiac membrane stabilization (does not lower potassium):

• Calcium gluconate 10%: 15-30 mL IV over 2-5 minutes 1
• Onset of action: 1-3 minutes 1
• If no effect within 5-10 minutes, repeat dose 1

Transcellular shift agents (lower potassium temporarily):

• Insulin regular 10 units IV push with dextrose 50% (D50W) 50 mL (25 grams): lowers potassium by 0.5-1.2 mEq/L within 30-60 minutes 1
• Albuterol 10-20 mg nebulized over 10 minutes: lowers potassium by 0.5-1.0 mEq/L within 30-60 minutes, can be used alone or to augment insulin effect 1
• Sodium bicarbonate 50 mEq IV over 5 minutes may be considered in severe metabolic acidosis with hyperkalemia, though not efficacious as monotherapy 1

Potassium removal:

• Newer potassium binders (patiromer or sodium zirconium cyclosilicate) are superior to sodium polystyrene sulfonate for maintaining normokalemia over time 1
• Urgent hemodialysis for severe hyperkalemia with uremic symptoms removes total body potassium load, corrects metabolic acidosis, and eliminates volume overload 1

Monitoring Protocol

• Continuous cardiac monitoring is required for severe hyperkalemia (K+ >6.5 mEq/L) or any ECG changes 1
• Recheck potassium within 1-2 hours after insulin/glucose administration 1
• Continue monitoring every 2-4 hours during acute treatment phase until stabilized 1

Chronic Hyperkalemia Management in CKD

For patients with stage 4 CKD and chronic hyperkalemia:

• Implement dietary potassium restriction, limiting foods rich in bioavailable potassium, especially processed foods 1
• Avoid salt substitutes containing potassium 1
• Initiate newer potassium binders (patiromer or sodium zirconium cyclosilicate) to maintain serum potassium 4.0-5.0 mEq/L while continuing RAAS inhibitor therapy 1
• Continue RAAS inhibitors whenever possible to slow CKD progression and improve cardiovascular outcomes 1

Monitoring for CKD patients:

• Check serum potassium and renal function within 1 week of starting potassium binder therapy 1
• Monitor weekly during dose titration phase 1
• After achieving stable dose: check at 1-2 weeks, 3 months, then every 6 months 1

RAAS Inhibitor Management

Dose adjustments based on potassium levels:

• K+ 4.5-5.0 mEq/L not on maximal RAASi therapy: initiate or up-titrate RAASi and closely monitor K+ 1
• K+ >5.0-<6.5 mEq/L not on maximal RAASi therapy: initiate an approved K+-lowering agent 1
• K+ >6.5 mEq/L: discontinue or reduce RAASi immediately and initiate K+-lowering agent as soon as K+ >5.0 mEq/L 1

Critical safety consideration: When initiating K+-lowering therapy, monitor closely not only for efficacy but also to protect against hypokalemia, which may be even more dangerous than hyperkalemia 1

---

Hyponatremia Management

For severe symptomatic hyponatremia (seizures, coma, altered mental status), immediately administer 3% hypertonic saline with a target correction of 6 mmol/L over 6 hours or until severe symptoms resolve, but never exceed 8 mmol/L total correction in 24 hours to prevent osmotic demyelination syndrome. 2

Initial Assessment and Classification

Determine three key factors:

1. Symptom severity: Severe (seizures, coma, altered mental status) vs. mild/asymptomatic 2
2. Acuity: Acute (<48 hours) vs. chronic (>48 hours) 2
3. Volume status: Hypovolemic, euvolemic, or hypervolemic 2

Essential laboratory workup:

• Serum sodium, serum osmolality, urine osmolality, urine sodium concentration 2
• Serum creatinine, electrolytes (potassium, calcium, magnesium) 2
• Thyroid-stimulating hormone (TSH) to rule out hypothyroidism 2
• Assessment of extracellular fluid volume status 2

Treatment Based on Symptom Severity

Severe Symptomatic Hyponatremia (seizures, coma, altered mental status):

• Administer 3% hypertonic saline immediately 2
• Target correction: 6 mmol/L over first 6 hours or until severe symptoms resolve 2
• Absolute maximum: 8 mmol/L in 24 hours to prevent osmotic demyelination syndrome 2
• Monitor serum sodium every 2 hours during initial correction 2
• Requires ICU admission for close monitoring 2

Mild/Asymptomatic Hyponatremia:

• Treatment based on volume status and underlying etiology 2
• Slower correction rate: 4-6 mmol/L per day for high-risk patients 2
• Monitor serum sodium every 4 hours after resolution of severe symptoms 2

Treatment Based on Volume Status

Hypovolemic Hyponatremia:

• Discontinue diuretics immediately 2
• Administer isotonic saline (0.9% NaCl) for volume repletion 2
• Initial infusion rate: 15-20 mL/kg/h, then 4-14 mL/kg/h based on response 2
• Urinary sodium <30 mmol/L has 71-100% positive predictive value for response to saline infusion 2

Euvolemic Hyponatremia (SIADH):

• Fluid restriction to 1 L/day is the cornerstone of treatment 2
• If no response to fluid restriction, add oral sodium chloride 100 mEq three times daily 2
• For severe symptoms: 3% hypertonic saline 2
• Pharmacological options for resistant cases: vasopressin receptor antagonists (tolvaptan 15 mg once daily), demeclocycline, or lithium 2

Hypervolemic Hyponatremia (cirrhosis, heart failure):

• Fluid restriction to 1-1.5 L/day for serum sodium <125 mmol/L 2
• Discontinue diuretics temporarily if sodium <125 mmol/L 2
• Consider albumin infusion in cirrhotic patients 2
• Avoid hypertonic saline unless life-threatening symptoms present, as it may worsen ascites and edema 2

Special Populations and High-Risk Considerations

Patients with advanced liver disease, alcoholism, malnutrition, or prior encephalopathy:

• Require even more cautious correction: 4-6 mmol/L per day maximum 2
• Higher risk of osmotic demyelination syndrome (0.5-1.5% in liver transplant recipients) 2

Neurosurgical Patients:

• Distinguish between SIADH and cerebral salt wasting (CSW)—treatment approaches differ fundamentally 2
• CSW treatment: Volume and sodium replacement with isotonic or hypertonic saline, NOT fluid restriction 2
• For severe CSW symptoms: 3% hypertonic saline plus fludrocortisone 0.1-0.2 mg daily in ICU 2
• In subarachnoid hemorrhage patients at risk of vasospasm: avoid fluid restriction, consider fludrocortisone or hydrocortisone 2

Correction Rate Guidelines

Standard correction rates:

• Maximum: 8 mmol/L in 24 hours for average-risk patients 2
• High-risk patients: 4-6 mmol/L per day, maximum 8 mmol/L in 24 hours 2
• For severe symptoms: correct 6 mmol/L over first 6 hours, then limit remaining correction to 2 mmol/L over next 18 hours 2

Calculating sodium deficit:

• Formula: Desired increase in Na (mEq/L) × (0.5 × ideal body weight in kg) 2

Management of Overcorrection

If sodium correction exceeds 8 mmol/L in 24 hours:

• Immediately discontinue current fluids and switch to D5W (5% dextrose in water) 2
• Consider administering desmopressin to slow or reverse the rapid rise 2
• Target: bring total 24-hour correction back to ≤8 mmol/L from starting point 2
• Watch for signs of osmotic demyelination syndrome (dysarthria, dysphagia, oculomotor dysfunction, quadriparesis) typically occurring 2-7 days after rapid correction 2

Common Pitfalls to Avoid

• Overly rapid correction of chronic hyponatremia (>8 mmol/L in 24 hours) leading to osmotic demyelination syndrome 2
• Inadequate monitoring during active correction 2
• Using fluid restriction in cerebral salt wasting (worsens outcomes) 2
• Failing to recognize and treat the underlying cause 2
• Using hypertonic saline in hypervolemic hyponatremia without life-threatening symptoms 2
• Ignoring mild hyponatremia (130-135 mmol/L) as clinically insignificant—it increases fall risk and mortality 2

---

Hypernatremia Management

For hypernatremia, use hypotonic fluids (0.45% NaCl or D5W) with a maximum correction rate of 0.4 mmol/L/hour or 10 mmol/L per 24 hours to prevent cerebral edema. 2

Fluid Selection

Primary hypotonic fluid options:

• 0.45% NaCl (half-normal saline): 77 mEq/L sodium, osmolarity ~154 mOsm/L—appropriate for moderate hypernatremia 2
• 0.18% NaCl (quarter-normal saline): ~31 mEq/L sodium—for more aggressive free water replacement 2
• D5W (5% dextrose in water): delivers no renal osmotic load, allows slow controlled decrease in plasma osmolality—preferred primary rehydration fluid 2

Avoid isotonic saline (0.9% NaCl) in hypernatremia:

• Delivers excessive osmotic load requiring 3 liters of urine to excrete osmotic load from just 1 liter of isotonic fluid 2
• Will worsen hypernatremia in patients unable to excrete free water appropriately 2

Correction Rate Guidelines

• Maximum correction rate: 0.4 mmol/L/hour or 10 mmol/L per 24 hours 2
• Corrections faster than 48-72 hours for severe hypernatremia associated with increased risk of pontine myelinolysis 2
• For patients with central pontine myelinolysis: reduce sodium at rate of 10-15 mmol/L per 24 hours 2

Initial Fluid Administration Rates

For children:

• 100 mL/kg/24 hours for first 10 kg 2
• 50 mL/kg/24 hours for 10-20 kg 2
• 20 mL/kg/24 hours for remaining weight 2

For adults:

• 25-30 mL/kg/24 hours 2

Special Clinical Scenarios

Patients with renal concentrating defects (nephrogenic diabetes insipidus):

• Require hypotonic fluid replacement to prevent hypernatremia 2
• Need ongoing hypotonic fluid administration to match excessive free water losses 2
• Isotonic fluids will worsen hypernatremia 2

Patients with voluminous diarrhea or severe burns:

• Require hypotonic fluids to match composition of losses while providing adequate free water 2

---

Hypocalcemia and Hypercalcemia Management

For symptomatic hypocalcemia with tetany or seizures, administer IV calcium gluconate 1-2 grams (10-20 mL of 10% solution) over 10-20 minutes, followed by continuous infusion if needed. 3

Hypocalcemia Treatment

Acute symptomatic hypocalcemia:

• IV calcium gluconate 10%: 10-20 mL (1-2 grams) over 10-20 minutes 3
• For ongoing symptoms: continuous infusion of 50-100 mL calcium gluconate 10% in 500-1000 mL D5W at 50 mL/hour 3
• Monitor serum calcium every 4-6 hours during active treatment 3

Chronic hypocalcemia:

• Oral calcium carbonate 1-2 grams elemental calcium daily in divided doses 3
• Vitamin D supplementation (calcitriol 0.25-0.5 mcg daily) if vitamin D deficiency present 3
• Check and correct magnesium levels, as hypomagnesemia impairs PTH secretion 3

Hypercalcemia Treatment

Severe hypercalcemia (>14 mg/dL or symptomatic):

• Aggressive IV hydration with normal saline 200-300 mL/hour initially 3
• Loop diuretics (furosemide 20-40 mg IV) after adequate hydration to enhance calcium excretion 3
• Bisphosphonates (zoledronic acid 4 mg IV or pamidronate 60-90 mg IV) for sustained effect 3
• Calcitonin 4 units/kg SC or IM every 12 hours for rapid but temporary effect 3

---

Hypomagnesemia and Hypermagnesemia Management

For severe symptomatic hypomagnesemia with cardiac manifestations, administer 1-2 grams magnesium sulfate IV over 15-30 minutes, followed by continuous infusion if needed. 1

Hypomagnesemia Treatment

Severe symptomatic (seizures, arrhythmias):

• Magnesium sulfate 1-2 grams (8-16 mEq) IV over 15-30 minutes 1
• For cardiac arrest with hypomagnesemia: 1-2 g MgSO4 IV push 1
• Continuous infusion: 1-2 grams/hour for 3-6 hours, then 0.5-1 gram/hour 1

Mild to moderate hypomagnesemia:

• Oral magnesium supplementation: 200-400 mg elemental magnesium daily, divided into 2-3 doses 1
• Use organic magnesium salts (aspartate, citrate, lactate) rather than oxide or hydroxide due to superior bioavailability 1
• Target magnesium level >0.6 mmol/L (>1.5 mg/dL) 1

Hypermagnesemia Treatment

Severe hypermagnesemia (>4 mEq/L with symptoms):

• Discontinue all magnesium-containing medications and supplements 3
• IV calcium gluconate 1-2 grams to antagonize cardiac and neuromuscular effects 3
• IV fluids and loop diuretics to enhance renal excretion 3
• Hemodialysis for severe cases with renal failure 3

---

Hypophosphatemia Management

For severe hypophosphatemia (<1.0 mg/dL), administer IV sodium phosphate or potassium phosphate 0.32-0.64 mmol/kg over 6 hours, with maximum single dose of 45 mmol phosphorus. 1

Severity-Based Treatment

Severe (<1.0 mg/dL):

• IV phosphate 0.44-0.64 mmol/kg (0.64-0.94 mEq/kg potassium), maximum 45 mmol phosphorus single dose 1
• Administer over 6 hours 1

Moderate (1.0-1.7 mg/dL):

• IV phosphate 0.32-0.43 mmol/kg (0.47-0.63 mEq/kg potassium) 1

Mild (1.8 mg/dL to lower normal):

• IV phosphate 0.16-0.31 mmol/kg (0.23-0.46 mEq/kg potassium) 1

Critical Pre-Administration Checks

• Verify serum potassium <4.0 mEq/L 1
• Check and normalize calcium first 1
• Confirm adequate urine output (≥0.5 mL/kg/hour) 1

Monitoring

• Monitor serum phosphorus, calcium, potassium, and magnesium closely during repletion 1
• In patients with moderate renal impairment (eGFR 30-60 mL/min/1.73 m²), start at low end of dose range 1

---

This comprehensive approach prioritizes immediate life-threatening conditions while providing specific, actionable guidance for each electrolyte disorder, with clear correction targets and monitoring parameters to optimize patient safety and outcomes.